ClinicalTrials.gg

TargetBeta

DRD3

dopamine receptor D3 · Dopamine receptors

5 programs in company-led studies act on DRD3, from 4 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
OlanzapineruleEli Lillyphase 4761 runningDRD2, DRD4, HTR2A, HTR2CChEMBL
rotigotineruleUCBphase 4641 runningDRD2, DRD4ChEMBL
PramipexoleruleBoehringer Ingelheimphase 4441 runningDRD2, DRD4ChEMBL
cariprazineruleAbbViephase 3414 runningDRD2ChEMBL
ABBV-932AbbViephase 2103 runningDRD2, HTR1Athe company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.